LeadIQ logo
Learn more at LeadIQ.com

Insights

AI Immunology Advantage Leverage Evaxion's AI-Immunology platform to offer personalized cancer vaccines and infectious disease candidates, targeting pharmaceutical and biotech partners seeking precision immunotherapies and accelerated development timelines.

Clinical Momentum Evaxion is advancing a clinical-stage oncology pipeline with EVX-01 and presenting three-year efficacy data at major conferences, presenting opportunities for collaborations, co-development, or licensing of successful assets.

Strategic Partnerships Recent collaboration with the Gates Foundation on polio vaccine design signals openness to public-private partnerships; explore opportunities for vaccine design, supply chain collaboration, or funding-enabled programs in underserved areas.

Awarded Credibility Recognition such as the Prix Galien UK Award enhances credibility with potential partners and investors, aiding in outreach, due diligence, and enterprise partnerships seeking validated digital health and AI-driven solutions.

Operational Readiness Executive leadership updates and a scalable tech stack (ISO 27001, continuous delivery, cloud-leaning infrastructure) indicate a mature operations foundation suitable for outsourcing, CDMO-like collaborations, or contract research partnerships.

Similar companies to Evaxion A/S

Evaxion A/S Tech Stack

Evaxion A/S uses 8 technology products and services including Grafana, Ansible, HashiCorp Terraform, and more. Explore Evaxion A/S's tech stack below.

Media & News

Evaxion A/S's Email Address Formats

Evaxion A/S uses at least 3 email formats:
Evaxion A/S Email FormatsExamplePercentage
Last@evaxion-biotech.comDoe@evaxion-biotech.com
65%
FL@evaxion-biotech.comJD@evaxion-biotech.com
35%
FL@evaxion.aiJD@evaxion.ai
100%

Frequently Asked Questions

What is Evaxion A/S's official website and social media links?

Minus sign iconPlus sign iconEvaxion A/S's official website is evaxion.ai and has social profiles on LinkedIn and Crunchbase.

How much revenue does Evaxion A/S generate?

Minus sign iconPlus sign icon As of July 2026, Evaxion A/S's annual revenue is estimated to be $1M - $10M.

What is Evaxion A/S's SIC code and NAICS code?

Minus sign iconPlus sign iconEvaxion A/S's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Evaxion A/S have currently?

Minus sign iconPlus sign iconAs of July 2026, Evaxion A/S has approximately 51 employees across 2 continents, including Europe and North America. Key team members include Chief Financial Officer: T. F. S., Chief Ai Officer, Founder: A. H. M. and Chief Scientific Officer: B. R. Explore Evaxion A/S's employee directory with LeadIQ.

What industry does Evaxion A/S belong to?

Minus sign iconPlus sign iconEvaxion A/S operates in the Biotechnology Research industry.

What technology does Evaxion A/S use?

Minus sign iconPlus sign iconEvaxion A/S's tech stack includes Grafana, Ansible, HashiCorp Terraform, Kubernetes, PostgreSQL, Dropbox, Microsoft 365 and Microsoft Azure.

What is Evaxion A/S's email format?

Minus sign iconPlus sign iconEvaxion A/S's email format typically follows the pattern of Last@evaxion-biotech.com. Find more Evaxion A/S email formats with LeadIQ.

How much funding has Evaxion A/S raised to date?

Minus sign iconPlus sign icon As of July 2026, Evaxion A/S has raised $114M in funding. The last funding round occurred on Oct 30, 2025 for $4.1M.

When was Evaxion A/S founded?

Minus sign iconPlus sign iconEvaxion A/S was founded in 2008.
Evaxion A/S logo

Evaxion A/S

Biotechnology ResearchHovedstaden, Denmark51-200 Employees

Evaxion A/S is a biotechnology research company based in Hørsholm, Denmark, focused on applying artificial intelligence to immunology. Its AI-Immunology platform is used to decode the human immune system in order to develop novel immunotherapies and vaccines for cancer, bacterial infections, and viral diseases, including personalized cancer vaccines and preclinical infectious disease programs. The company operates in a clinical-stage and preclinical space, targeting unmet medical needs by offering approaches that aim to design targeted treatments and vaccines. Its activities position it within the TechBio segment, combining computational methods with a focus on immune-related therapies. In addition to its core pipelines, Evaxion has engaged in collaborations and activities such as presenting AI-based vaccine design concepts and pursuing partnerships, including with the Gates Foundation, as part of its ongoing research and development efforts.

Section iconCompany Overview

Website
evaxion.ai
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $114M

    Evaxion A/S has raised a total of $114M of funding over 9 rounds. Their latest funding round was raised on Oct 30, 2025 in the amount of $4.1M as a Post IPO Equity.

  • $1M - $10M

    Evaxion A/S's revenue is estimated to be in the range of $1M - $10M

Company Leadership

  • Chief Financial Officer at Evaxion A/S
    T. F. S.
    Chief Financial Officer
    Mobile Phone
  • Chief Ai Officer, Founder at Evaxion A/S
    A. H. M.
    Chief Ai Officer, Founder
    Mobile Phone
  • Chief Scientific Officer at Evaxion A/S
    B. R.
    Chief Scientific Officer
    Mobile Phone
  • Vice President Clinical Development at Evaxion A/S
    B. O. W.
    Vice President Clinical Development
    Mobile Phone
  • Vp Investor Relations at Evaxion A/S
    S. M.
    Vp Investor Relations
    Mobile Phone

Employee Directory

  • Vice President Clinical Development at Evaxion A/S
    B. O. W.
    Vice President Clinical Development
    Mobile Phone
  • Vice President, Infectious Disease Vaccine Development at Evaxion A/S
    P. C.
    Vice President, Infectious Disease Vaccine Development
    Mobile Phone
  • Director, Head Of Business Development at Evaxion A/S
    S. F.
    Director, Head Of Business Development
    Mobile Phone
  • Cmc Project Vp at Evaxion A/S
    T. S. J.
    Cmc Project Vp
    Mobile Phone
  • Vp Investor Relations at Evaxion A/S
    S. M.
    Vp Investor Relations
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.